Indaptus Therapeutics (Indaptus Therapeutics) Total Payout Yield % : 0.00 (As of Apr. 29, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Indaptus Therapeutics Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Indaptus Therapeutics's current Total Payout Yield % is 0.00%.

Indaptus Therapeutics Total Payout Yield % Historical Data

The historical data trend for Indaptus Therapeutics's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indaptus Therapeutics Total Payout Yield % Chart

Indaptus Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Payout Yield %

-10.62

Indaptus Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Payout Yield %	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Indaptus Therapeutics's Total Payout Yield %

For the Biotechnology subindustry, Indaptus Therapeutics's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Indaptus Therapeutics's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Indaptus Therapeutics's Total Payout Yield % falls into.

Indaptus Therapeutics Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Indaptus Therapeutics's Total Payout Yield % for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Market Cap
	=	- (0	+	0	+	0)	/	14.785848
	=	0.00%

Indaptus Therapeutics's annualized Total Payout Yield % for the quarter that ended in Dec. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0	+	0)	*	4	/	14.785848
	=	0.00%

Indaptus Therapeutics Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

Indaptus Therapeutics Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Indaptus Therapeutics's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Indaptus Therapeutics (Indaptus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Indaptus Therapeutics Inc (NAS:INDP) » Definitions » Total Payout Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Columbus Circle, 15th Floor, New York, NY, USA, 10019

Website

https://www.indaptusrx.com

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.

Executives

Glen R. Anderson	10 percent owner	3274 ROSS ROAD, PALO ALTO CA 94303
Roger J. Waltzman	officer: Chief Medical Officer	C/O JAGUAR ANIMAL HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Robert Martell	director	4 MAGUIRE ROAD, LEXINGTON MA 02421
Boyan Vesselinov Litchev	officer: Chief Medical Officer	13357 RUSSET LEAF LN., SAN DIEGO CA 92129
Jeffrey A Meckler	director, officer: Chief Executive Officer	740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
Walt Addison Linscott	officer: Chief Business Officer	1860 MONTREAL ROAD, TUCKER GA 30084
Michael James Newman	director, 10 percent owner, officer: Chief Scientific Officer	C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Mark John Gilbert	director	13731 NORTHWOOD RD., NW, SEATTLE WA 98177
Brian O'callaghan	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Hoonmo Lee	director, 10 percent owner	C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Anthony J Maddaluna	director	PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
William B Hayes	director	231 MAPLE AVENUE, BURLINGTON NC 27215
Roger Pomerantz	director	711 HARVEST HILL ROAD, CHALFONT PA 18914
Hila Karah	director	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Nir Sassi	officer: Chief Financial Officer	3 ELUL STREET, APT. 6, MODIIN L3 7176397